The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bortezomib (BZB)-associated adverse events (AE) in patients with multiple myeloma (MM).
L. Katragadda
No relevant relationships to disclose
N. Sanathkumar
No relevant relationships to disclose
M. Veeraputhiran
No relevant relationships to disclose
A. Restrepo
No relevant relationships to disclose
S. Haider
No relevant relationships to disclose
J. Muzaffar
No relevant relationships to disclose
B. Barlogie
Research Funding - Celgene; Millennium
E. J. Anaissie
No relevant relationships to disclose